Clinical Trials Directory

Trials / Completed

CompletedNCT01039818

Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism

Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism: A Clinical Trial With Historical Control

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Hospital de Clinicas de Porto Alegre · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether higher doses of radioiodine increase treatment efficacy in severe Graves' disease.

Detailed description

Graves' disease (GD) is the most frequent cause of hyperthyroidism, affecting mainly women aged 40-60 years. Radioiodine (¹³¹I), introduced in 1941, has become a cornerstone in the treatment of GD hyperthyroidism. Because of its safety, low costs and rapid effect, it is considered a first line therapy in the United States. However, treatment failure occurs in about 15-25% of patients treated with radioiodine. Patients not cured with the first dose of radioiodine usually present severe hyperthyroidism, characterized by large goiter, high 24-hour radioiodine uptake (24h-RAIU) and very high levels of thyroid hormones. We have previously shown that large goiter (≥48ml) is an independent predictor of treatment failure. In these patients, the therapeutic failure was 40.0% while in patients with smaller goiter was only 6.5% (P=0.005; unpublished). It is generally accepted that higher doses of radioiodine improves cure rates. Indeed, a recent meta-analysis found a correlation between radioiodine dose and therapeutic success in GD patients. To our knowledge, there are no published studies evaluating cure rates with different radioiodine doses in severe GD.

Conditions

Interventions

TypeNameDescription
RADIATIONRadioiodineA unique dose of 200µCi of ¹³¹I/ml/24-RAIU
RADIATIONRadioiodineA unique dose of 250µCi of ¹³¹I/ml/24-RAIU

Timeline

Start date
1997-02-01
Primary completion
2011-08-01
Completion
2011-08-01
First posted
2009-12-25
Last updated
2012-09-06

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT01039818. Inclusion in this directory is not an endorsement.